Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.45 |
| ▸ | PRCP | P42785 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19703683 | 0.96 | SMN1; SMN2 (0.43) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL2779228 | 0.93 | NAAA (0.55) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL14872066 | 0.93 | NAAA (0.55) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL11990499 | 0.92 | SMN1; SMN2 (0.53) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL21659263 | 0.89 | NAMPT (0.42) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL28823421 | 0.89 | SMN1; SMN2 (0.51) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL4761616 | 0.89 | SMN1; SMN2 (0.49) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL19703687 | 0.89 | SMN1; SMN2 (0.38) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL19703588 | 0.89 | CNR1 (0.38) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL23347014 | 0.88 | SMN1; SMN2 (0.43) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| WO-2016071856-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS AG (CH) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | NAAA 1609/4885SMN1; SMN2 2500/4885GNAI3 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.